Deletion of the C26 Methyl Substituent from the Bryostatin Analogue Merle 23 Has Negligible Impact on Its Biological Profile and Potency |
| |
| Authors: | Dr. Xiguang Zhao Dr. Noemi Kedei Dr. Alexandra Michalowski Nancy E. Lewin Dr. Gary E. Keck Dr. Peter M. Blumberg |
| |
| Affiliation: | 1. Department of Chemistry, University of Utah, Salt Lake City, Utah, USA;2. Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA |
| |
| Abstract: | Important strides are being made in understanding the effects of structural features of bryostatin 1, a candidate therapeutic agent for cancer and dementia, in conferring its potency toward protein kinase C and the unique spectrum of biological responses that it induces. A critical pharmacophoric element in bryostatin 1 is the secondary hydroxy group at the C26 position, with a corresponding primary hydroxy group playing an analogous role in binding of phorbol esters to protein kinase C. Herein, we describe the synthesis of a bryostatin homologue in which the C26 hydroxy group is primary, as it is in the phorbol esters, and show that its biological activity is almost indistinguishable from that of the corresponding compound with a secondary hydroxy group. |
| |
| Keywords: | drug design natural products protein kinase C signal transduction structure– activity relationships |
|
|
